Antisecretory drugs, Helicobacter pylori infection and symptom relief in GORD: Still an unexplored triangle

Digestive and Liver Disease

Volumn 37, Issue 7, 2005, Pages 468-474

  Scarpignato, C ^a  

^a UNIVERSITY OF PARMA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTACID AGENT; CLARITHROMYCIN; ESOMEPRAZOLE; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; METRONIDAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; PUMAPRAZOLE; RABEPRAZOLE; RANITIDINE; STOMACH SECRETION INHIBITOR; UNCLASSIFIED DRUG; 2 [[(2 PYRIDYL)METHYL]SULFINYL]BENZIMIDAZOLE DERIVATIVE; DRUG DERIVATIVE; PROTON PUMP;

ARTICLE; CLINICAL TRIAL; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENCY; DRUG TOLERANCE; DYSPEPSIA; GASTRODUODENAL ULCER; GASTROESOPHAGEAL REFLUX; HEARTBURN; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; META ANALYSIS; OUTCOMES RESEARCH; PH MEASUREMENT; QUALITY OF LIFE; STOMACH ACID SECRETION; STOMACH PH; SYSTEMATIC REVIEW; DRUG ANTAGONISM; MICROBIOLOGY; NOTE; REFLUX ESOPHAGITIS;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ESOPHAGITIS, PEPTIC; FAMOTIDINE; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HISTAMINE H2 ANTAGONISTS; HUMANS; OMEPRAZOLE; PROTON PUMPS; QUALITY OF LIFE;

EID: 26944434855     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2005.03.002     Document Type: Note

References (88)

1. Scarpignato C., and Galmiche J.P. Functional evaluation in esophageal disease (1994), Karger, Basel p. 1-372
2. Bytzer P. Goals of therapy and guidelines for treatment success in symptomatic gastroesophageal reflux disease patients. Am J Gastroenterol 98 Suppl. 3 (2003) S31-S39
3. Kamolz T., Pointner R., and Velanovich V. The impact of gastroesophageal reflux disease on quality of life. Surg Endosc 17 (2003) 1193-1199
4. Wiklund I. Review of the quality of life and burden of illness in gastroesophageal reflux disease. Dig Dis 22 (2004) 108-114
5. Tack J., and Fass R. Review article: approaches to endoscopic-negative reflux disease: part of the GERD spectrum or a unique acid-related disorder?. Aliment Pharmacol Ther 19 Suppl. 1 (2004) 28-34
6. Meining A., and Classen M. The role of diet and lifestyle measures in the pathogenesis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 95 (2000) 2692-2697
7. Dent J., Armstrong D., Delaney B., Moayyedi P., Talley N.J., and Vakil N. Symptom evaluation in reflux disease: workshop background, processes, terminology, recommendations, and discussion outputs. Gut 53 Suppl. 4 (2004) 1-24
8. Richter J.E., Kahrilas P.J., Johanson J., Maton P., Breiter J.R., et al., Esomeprazole Study Investigators. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol 96 (2001) 656-665
9. Castell D.O., Kahrilas P.J., Richter J.E., Vakil N.B., Johnson D.A., Zuckerman S., et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol 97 (2002) 575-583
10. Farley A., Wruble L.D., and Humphries T.J. Rabeprazole versus ranitidine for the treatment of erosive gastroesophageal reflux disease: a double-blind, randomized clinical trial. Am J Gastroenterol 95 (2000) 1894-1899
11. Carlsson R., Dent J., Watts R., Riley S., Sheikh R., Hatlebakk, et al., International GORD Study Group. Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. Eur J Gastroenterol Hepatol 10 (1998) 119-124
12. Carlsson R., Frison L., Lundell L., and Dent J. Relationship between symptoms, endoscopic findings and treatment outcome in reflux esophagitis. Gastroenterology 110 Suppl. (1996) A77
13. Huang J.Q., and Hunt R.H. pH, healing rate and symptom relief in acid-related diseases. Yale J Biol Med 69 (1996) 159-174
14. Howden C.W., Burget D.W., and Hunt R.H. Appropriate acid suppression for optimal healing of duodenal ulcer and gastro-oesophageal reflux disease. Scand J Gastroenterol 29 Suppl. 201 (1994) 79-82
15. Wolfe M.M., and Sachs G. Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome. Gastroenterology 118 2 Suppl. 1 (2000) S9-S31
16. Burget D.W., Chiverton S.G., and Hunt R.H. Is there an optimal degree of acid suppression for healing of duodenal ulcers? A model of the relationship between ulcer healing and acid suppression. Gastroenterology 99 (1990) 345-351
17. Poynard T., Lemaire M., and Agostini H. Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer. Eur J Gastroenterol Hepatol 7 (1995) 661-665
18. Salas M., Ward A., and Caro J. Are proton pump inhibitors the first choice for acute treatment of gastric ulcers? A meta analysis of randomized clinical trials. BMC Gastroenterol 15 (2002) 17-23
19. Scarpignato C. Towards the ideal regimen for Helicobacter pylori eradication: the search continues. Dig Liver Dis 36 (2004) 243-247
20. Gisbert J.P., Gonzalez L., Calvet X., Roque M., Gabriel R., and Pajares J.M. Proton pump inhibitor, clarithromycin and either amoxicillin or nitroimidazole: a meta-analysis of eradication of Helicobacter pylori. Aliment Pharmacol Ther 14 (2000) 1319-1328
21. Vallve M., Vergara M., Gisbert J.P., and Calvet X. Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis. Aliment Pharmacol Ther 16 (2002) 1149-1156
22. Malfertheiner P., Mégraund F., O'Morain C., Hangin A.P.S., Jones R., Axon, et al., European Helicobacter pylori Study Group (EHPSG). Current Concepts in the management of Helicobacter pylori infection-The Maastricht 2-2000 Consensus report. Aliment Pharmacol Ther 16 (2002) 167-180
23. Metz D.C., Pisegna J.R., Fishbeyn V.A., Benya R.V., and Jensen R.T. Control of gastric acid hypersecretion in the management of patients with Zollinger-Ellison syndrome. World J Surg 17 (1993) 468-480
24. Metz D.C., and Jensen R.T. Advances in gastric antisecretory therapy in Zollinger-Ellison. Front Gastrointest Res 23 (1995) 240-257
25. 2-antagonist refractory ulcers. Digestion 44 Suppl. 1 (1989) 31-39
26. Bell N.J., Burget D., Howden C.W., Wilkinson J., and Hunt R.H. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 51 Suppl. 1 (1992) 59-67
27. Bell N.J., and Hunt R.H. Role of gastric acid suppression in the treatment of gastro-oesophageal reflux disease. Gut 33 (1992) 118-124
28. Chiba N., De Gara C.J., Wilkinson J.M., and Hunt R.H. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 112 (1997) 1798-1810
29. van Pinxteren B., Numans M.E., Lau J., de Wit N.J., Hungin A.P., and Bonis P.A. Short-term treatment of gastroesophageal reflux disease. J Gen Intern Med 18 (2003) 755-763
30. Scarpignato C., and Pelosini I. Prevention and treatment of non-steroidal anti-inflammatory drug-induced gastro-duodenal damage: rationale for the use of antisecretory compounds. Ital J Gastroenterol Hepatol 31 Suppl. 1 (1999) S63-S72
31. Lazzaroni M., and Bianchi Porro G. Prophylaxis and treatment of non-steroidal anti-inflammatory drug-induced upper gastrointestinal side-effects. Dig Liver Dis 33 Suppl. 2 (2001) S44-S58
32. Stedman C.A.M., and Barclay M.L. Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Aliment Pharmacol Ther 14 (2000) 963-978
33. McColl K.E.L., and Kennerley P. Proton pump inhibitors-differences emerge in the hepatic metabolism. Dig Liver Dis 34 (2002) 461-467
34. Thomson A.B.R. Are the orally administered proton pump inhibitors equivalent? A comparison of lansoprazole, omeprazole, pantoprazole, and rabeprazole. Curr Gastroenterol Rep 2 (2000) 482-493
35. Langman M.J.S. Which PPI?. Gut 49 (2001) 309-310
36. Kromer W., Horbach S., and Lühmann R. Relative efficacies of gastric proton pump inhibitors: their clinical and pharmacological basis. Pharmacology 59 (1999) 57-77
37. Guidance on the use of proton pump inhibitors in the treatment of dyspepsia. NICE, UK: Technology Appraisal Guidance No. 7; 2000 (http://www.nice.org.uk).
38. Edwards S.J., Lind T., and Lundell L. Systematic review of proton pump inhibitors for the acute treatment of reflux oesophagitis. Aliment Pharmacol Ther 15 (2001) 1729-1736
39. Edwards S.J., Lind T., and Lundell L. Systematic review of proton pump inhibitors for the maintenance of healed reflux oesophagitis. J Drug Ass 5 (2002) 165-178
40. Gisbert J.P., and Pajares J.M. Esomeprazole-based therapy in Helicobacter pylori eradication: a meta-analysis. Dig Liver Dis 36 (2004) 253-259
41. Anagnostopoulos G.K., Tsiakos S., Margantinis G., Kostopoulos P., and Arvanitidis D. Esomeprazole versus omeprazole for the eradication of Helicobacter pylori infection: results of a randomized controlled study. J Clin Gastroenterol 38 (2004) 503-506
42. 2-receptor antagonists in the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 9 Suppl. 1 (1995) 9-14
43. 2 de l'histamine. Gastroenterol Clin Biol 23 (1999) S78-S89
44. 2-receptor antagonists. An overview. Scand J Gastroenterol 27 Suppl. 193 (1992) 14-19
45. Komazawa Y., Adachi K., Mihara T., Ono M., Kawamura A., Fujishiro H., et al. Tolerance to famotidine and ranitidine treatment after 14 days of administration in healthy subjects without Helicobacter pylori infection. J Gastroenterol Hepatol 18 (2003) 678-682
46. Sandvik A.K., Brenna E., and Waldum H.L. Review article: the pharmacological inhibition of gastric acid secretion: tolerance and rebound. Aliment Pharmacol Ther 11 (1997) 1013-1018
47. Verdu E.F., Armstrong D., Fraser R., Viani F., Idström J.-P., Cederberg C., et al. Effect of Helicobacter pylori status on intragastric pH during treatment with omeprazole. Gut 36 (1995) 539-543
48. Verdu E.F., Armstrong D., Idström J.-P., Labenz J., Stolte M., Dorta G., et al. Effect of curing Helicobacter pylori infection on intragastric pH during treatment with omeprazole. Gut 37 (1995) 743-748
49. Labenz J., Tillenburg B., Peitz U., Idström J.-P., Verdu E.F., Stolte M., et al. Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcer. Gastroenterology 110 (1996) 725-732
50. Verdu E.F., Armstrong D., Idström J.-P., Labenz J., Stolte M., Borsch G., et al. Intragastric pH during treatment with omeprazole: role of H. pylori and H. pylori-associated gastritis. Scand J Gastroenterol 31 (1996) 1151-1156
51. Labenz J., Tillenburg B., Peitz U., Borsch G., Idström J.-P., Verdu E., et al. Efficacy of omeprazole one year after cure of Helicobacter pylori infection in duodenal ulcer patients. Am J Gastroenterol 92 (1997) 576-581
52. Gillen D., Wirz A.A., Neithercut W.D., Ardill J.E.S., and McColl K.E.L. Helicobacter pylori infection potentiates the inhibition of gastric acid secretion by omeprazole. Gut 44 (1999) 468-475
53. Van Herwaarden M.A., Samsom M., Van Nispen C.H.M., Mulder P.G.H., and Smout A.J.P.M. The effect of Helicobacter pylori eradication on intragastric pH during dosing with lansoprazole or ranitidine. Aliment Pharmacol Ther 13 (1999) 731-740
54. Koop H., Kuly S., Flug M., Eissele R., Monnikes H., Rose K., et al. Intragastric pH and serum gastrin during administration of different doses of pantoprazole in healthy subjects. Eur J Gastroenterol Hepatol 8 (1996) 915-918
55. Williams M.P., Usselmann B., Chilton A., Sercombe J., Nwokolo C.U., and Pounder R.E. Eradication of Helicobacter pylori increases nocturnal intragastric acidity during dosing with rabeprazole, omeprazole, lansoprazole and placebo. Aliment Pharmacol Ther 17 (2003) 775-783
56. Martinek J., Blum A.L., Stolte M., Hartmann M., Verdu E.F., Luhmann R., et al. Effects of pumaprazole (BY841), a novel reversible proton pump antagonist, and of omeprazole, on intragastric acidity before and after cure of Helicobacter pylori infection. Aliment Pharmacol Ther 13 (1999) 27-34
57. Labenz J., Tillenburg B., Peitz U., Verdú E.F., Stolte M., Blum A.L., et al. Effect of curing H. pylori (HP) infection on the pH-raising effect of ranitidine (RAN) in duodenal ulcer (DU) patients. Gastroenterology 110 (1996) A165
58. Labenz J., Tillenburg B., Peitz U., Verdu E., Stolte M., Börsch G., et al. Effect of curing Helicobacter pylori infection on intragastric acidity during treatment with ranitidine in patients with duodenal ulcer. Gut 41 (1997) 33-36
59. Bercik P., Verdú E.F., Armstrong D., Cederberg C., Idström J.-P., Stolte M., et al. H. pylori-related increase in omeprazole (OME) effect is associated with ammonia production. Gastroenterology 110 (1996) A64
60. Pantoflickova D., Blum A.L., and Bercik P. Omeprazole: Helicobacter pylori makes thee greater yet!. Gut 44 (1999) 448-449
61. Cave D.R., and Vargas M. Effect of a Campylobacter pylori protein on acid secretion by parietal cells. Lancet ii (1989) 187-189
62. + ATPase. Gut 35 (1994) 1176-1180
63. Kobayashi H., Kamiya S., Suzuki T., Kohda K., Muramatsu S., Kurumada T., et al. The effect of Helicobacter pylori on gastric acid secretion by isolated parietal cells from a guinea pig. Association with production of vacuolating toxin by H. pylori. Scand J Gastroenterol 31 (1996) 428-433
64. Logan R.P.H., Walker M.M., Misiewicz J.J., Gummett P.A., Karim Q.N., and Baron J.H. Changes in the intragastric distribution of Helicobacter pylori during treatment with omeprazole. Gut 36 (1995) 12-16
65. Stolte M., Meining A., Schmitz J.M., Alexandridis T., and Seifert E. Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during 12 months of treatment with omeprazole and lansoprazole in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 12 (1998) 247-253
66. El-Omar E.M., Oien K., El-Nujumi A., Gillen D., Wirz A., Dahill S., et al. Helicobacter pylori infection and chronic gastric acid hyposecretion. Gastroenterology 113 (1997) 15-24
67. Calam J., Gibbons A., Healey Z.V., Bliss P., and Arebi N. How does Helicobacter pylori cause mucosal damage? Its effect on acid and gastrin physiology. Gastroenterology 113 Suppl. 6 (1997) S43-S49
68. McColl K.E., el-Omar E., and Gillen D. Helicobacter pylori gastritis and gastric physiology. Gastroenterol Clin North Am 29 (2000) 687-703
69. Taché Y., and Saperas E. Potent inhibition of gastric acid secretion and ulcer formation by centrally and peripherally administered interleukin-1α. Ann NY Acad Sci 664 (1992) 353-368
70. Negrini R., Lisato L., Zanella I., Cavazzini L., Gullini S., Villanacci V., et al. Helicobacter pylori infection induces antibodies cross-reacting with human gastric mucosa. Gastroenterology 101 (1991) 437-445
71. Scarpignato C., and Pelosini I. Antisecretory drugs for eradication of Helicobacter pylori: antibacterial activity and synergism with antimicrobial agents. Progr Basic Clin Pharmacol 11 (1999) 136-180
72. Holtmann G., Cain C., and Malfertheiner P. Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole. Gastroenterology 117 (1999) 11-16
73. Hattlebakk J.G., Hyggen A., Madsen P.H., Walle P.O., Schulz T., Mowinckel P., et al., Norwegian Heartburn Study Group. Heartburn treatment in primary care: randomised, double blind study for 8 weeks. Br Med J 319 (1999) 550-553
74. Malfertheiner P., Leodolter A., Vieth M., Jaspersen D., Labenz J., Meyer-Sabellek W., et al. Which factors have an impact on healing and symptom relief in patients with erosive and non-erosive GERD treated with esomeprazole? An analysis based on the ProGERD study initiative. Gastroenterology 122 (2002) A198
75. Vakil N.B., Traxler B.M., and Levine D. Symptom response and healing of erosive esophagitis with proton-pump inhibitors in patients with Helicobacter pylori infection. Am J Gastroenterol 99 (2004) 1437-1441
76. Wit N.J., Boer W.A., Geldof H., Hazelhoff B., Bergmans P., Tytgat G.N., et al. Treatment of gastro-oesophageal reflux disease with rabeprazole in primary and secondary care: does Helicobacter pylori infection affect proton pump inhibitor effectiveness?. Aliment Pharmacol Ther 20 (2004) 451-458
77. Graham D.Y., Malaty H.M., Evans Jr. D.G., Klein P.D., and Adam E. Epidemiology of Helicobacter pylori in an asymptomatic population in the United States. Effect of age, race, and socioeconomic status. Gastroenterology 100 (1991) 1495-1501
78. 2-receptor antagonists. Aliment Pharmacol Ther 7 Suppl. 2 (1993) 27-33
79. 2 receptor antagonists. Aliment Pharmacol Ther 20 (2004) 559-565
80. Adachi K., Hashimoto T., Komazawa Y., Mihara T., Furuta K., Fujishiro H., et al. Helicobacter pylori infection influences symptomatic response to anti-secretory therapy in patients with GERD-crossover comparative study with famotidine and low-dose lansoprazole. Dig Liver Dis 37 (2005) 485-490
81. 2-receptor antagonists in the treatment of functional (nonulcer) dyspepsia: a meta-analysis of randomized controlled clinical trials. Aliment Pharmacol Ther 15 (2000) 1291-1299
82. Earnest D., Robinson M., Rodriguez-Stanley S., Ciociola A.A., Jaffe P., Silver M.T., et al. Managing heartburn at the 'base' of the GERD 'iceberg': effervescent ranitidine 150 mg b.d. provides faster and better heartburn relief than antacids. Aliment Pharmacol Ther 14 (2000) 911-918
83. Robinson M., Rodriguez-Stanley S., Ciociola A.A., Filinto J., Zubaidi S., Miner Jr. P.B., et al. Synergy between low-dose ranitidine and antacid in decreasing gastric and oesophageal acidity and relieving meal-induced heartburn. Aliment Pharmacol Ther 15 (2001) 1365-1374
84. Peghini P.L., Katz P.O., Bracy N.A., and Castell D.O. Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol 9 (1998) 763-767
85. Tutuian R., Katz P.O., and Castell D.O. Nocturnal acid breakthrough: pH, drugs and bugs. Eur J Gastroenterol Hepatol 16 (2004) 441-443
86. 2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology 122 (2002) 625-632
87. Cross L.B., and Justice L.N. Combination drug therapy for gastroesophageal reflux disease. Ann Pharmacother 36 (2002) 912-916
88. Guda N., Mueller R., and Vakil N. The effect of over the counter ranitidine (75 mg) on nighttime heartburn in patients with erosive esophagitis on daily proton pump inhibitor maintenance therapy. Gastroenterology 124 (2003) 539A